LAE-32
From Wikipedia, the free encyclopedia
 |
|
|
LAE-32
|
|
| Systematic (IUPAC) name | |
| 6aR,9R)-N-ethyl-7-methyl-4,6,6a,7,8,9- hexahydroindolo-[4,3-fg]quinoline-9-carboxamide |
|
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | ? |
| Chemical data | |
| Formula | C18H21N3O |
| Mol. mass | 295.378 g/mol |
| Synonyms | LAE, Lysergic acid ethylamide, d-lysergic acid ethylamide, d-ethyllysergamide, |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | hepatic |
| Half life | ? |
| Excretion | renal |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Oral |
D-Lysergic Acid Ethylamide, (LAE-32) is a derivative of ergine. It is reported to have some LSD-like effects but is weaker and shorter lasting, with an active dose reported to be between 0.5 and 1.5 milligrams.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
|
|||||
